Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES R HART

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1215915871
CMS profile
326600
Location
FRANKLIN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$10,004.86

75 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES R HART

NPI 1215915871 · CMS profile ID 326600

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

FRANKLIN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215915871?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES R HART, NPI 1215915871, CMS profile ID 326600. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215915871?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JAMES R HART, NPI 1215915871, CMS profile ID 326600. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215915871?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JAMES R HART, NPI 1215915871, CMS profile ID 326600, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–75 of 75 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1215915871?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

75 matching records · $10,004.86 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 75 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–75 of 75.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $15.0004/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241332878 CMS
E.R. Squibb & Sons, L.L.C. $36.8804/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184836309 CMS
Teva Pharmaceuticals USA, Inc. $11.6604/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247326900 CMS
Neurocrine BioSciences, Inc. $19.3404/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243028712 CMS
Janssen Pharmaceuticals, Inc $17.7304/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174897943 CMS
Neurocrine BioSciences, Inc. $30.3003/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242987153 CMS
Vanda Pharmaceuticals Inc. $35.6603/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232970346 CMS
Lundbeck LLC $26.2103/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251803228 CMS
Teva Pharmaceuticals USA, Inc. $23.9803/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247326898 CMS
Vanda Pharmaceuticals Inc. $30.3403/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232970344 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $20.1903/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241332876 CMS
Vanda Pharmaceuticals Inc. $36.2202/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232970342 CMS
Vanda Pharmaceuticals Inc. $6.8602/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232970340 CMS
Alkermes, Inc. $17.3302/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222518887 CMS
Teva Pharmaceuticals USA, Inc. $71.4002/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1247326696 CMS
Teva Pharmaceuticals USA, Inc. $2,996.0002/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247326698 CMS
Teva Pharmaceuticals USA, Inc. $13.0402/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247326868 CMS
Vanda Pharmaceuticals Inc. $26.3102/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232970338 CMS
Janssen Pharmaceuticals, Inc $17.0401/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174897761 CMS
Janssen Pharmaceuticals, Inc $5.4501/29/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1174897773 CMS
Neurocrine BioSciences, Inc. $15.7501/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243040863 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $14.1101/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241332874 CMS
E.R. Squibb & Sons, L.L.C. $19.4101/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184836287 CMS
Janssen Pharmaceuticals, Inc $17.9501/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174898223 CMS
Neurocrine BioSciences, Inc. $16.6401/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243038351 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,397.68 70
PY2020 $1,205.38 62
PY2021 $1,302.58 69
PY2022 $1,206.21 69
PY2023 $17,815.40 76
PY2024 $14,160.41 73
PY2025 $10,004.86 75

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $47,212.60 52
PY2024 Principal investigator $26,411.14 38
PY2023 Principal investigator $6,818.00 10
PY2022 Principal investigator $7,950.00 1
PY2021 Principal investigator $59,570.40 14
PY2020 Principal investigator $11,915.00 4
PY2019 Principal investigator $13,275.47 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

52 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,818.88 12/31/2025 Non-covered Recipient Entity
PSYCHIATRIC CONSULTANTS PC
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies No dispute reported 06/30/2026 1202533185
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 12/17/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244040965
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 12/17/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041029
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 12/17/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041031
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 12/17/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041033
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 12/17/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041035
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 12/17/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041037
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 11/19/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244040963
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 11/19/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041039
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 11/19/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041041
Principal investigator 1 ABBVIE INC. $1,783.28 10/20/2025 Non-covered Recipient Entity
PSYCHIATRIC CONSULTANTS PC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202517449
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 10/10/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244040961
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 10/10/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041043
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 10/10/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041045
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 10/10/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041047
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 10/10/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041049
Principal investigator 1 ABBVIE INC. $500.00 09/24/2025 Non-covered Recipient Entity
PSYCHIATRIC CONSULTANTS PC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202512176
Principal investigator 1 Vanda Pharmaceuticals Inc. $9,500.00 08/21/2025 Non-covered Recipient Entity
PSYCHIATRIC CONSULTANTS PC
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder No dispute reported 06/30/2026 1232946144
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 08/07/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244040959
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 08/07/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041003
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 08/07/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041025
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 08/07/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041027
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 08/07/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041051
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 08/07/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041053
Principal investigator 1 ABBVIE INC. $11,027.00 07/02/2025 Non-covered Recipient Entity
PSYCHIATRIC CONSULTANTS PC
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202496033
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,500.00 06/05/2025 Non-covered Recipient Entity
Psychiatric Consultants
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1235994431
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244040957
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041005
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041007
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041009
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041011
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041013
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041015
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041017
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041019
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041021
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 05/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041023
Principal investigator 1 ABBVIE INC. $447.49 04/02/2025 Non-covered Recipient Entity
PSYCHIATRIC CONSULTANTS PC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202468511
Principal investigator 1 ABBVIE INC. $2,842.95 03/19/2025 Non-covered Recipient Entity
PSYCHIATRIC CONSULTANTS PC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464682
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 03/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041067
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 03/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041249
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 03/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041251
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 03/14/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041253
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 01/22/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041063
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $227.00 01/22/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041065
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 01/22/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041235
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 01/22/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041237
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 01/22/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041239
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 01/22/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041241
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 01/22/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041243
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 01/22/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041245
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $362.00 01/22/2025 Non-covered Recipient Entity
Psychiatric Consultants, PC
TV50717-CNS-40223 No dispute reported 06/30/2026 1244041247